Results 21 to 30 of about 89,290 (238)

Susceptibility of OXA-48-producing Enterobacterales to imipenem-relebactam, meropenem-vaborbactam and ceftazidime-avibactam.

International Journal of Antimicrobial Agents, 2022
BACKGROUND Relebactam and vaborbactam are among the last β-lactamase inhibitors marketed. They were originally designed to inhibit the Ambler class A carbapenemase KPC.
R. Bonnin, Sandrine Bernabeu, C. Emeraud, Elodie Creton, Océane Vanparis, T. Naas, A. Jousset, L. Dortet   +7 more
semanticscholar   +1 more source

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

Infection and Drug Resistance, 2022
Purpose Critically ill patients with preserved or increased renal function have been shown to be at risk of underexposure to meropenem. Although many meropenem population pharmacokinetic (PK) models have been published, there is no large prospective ...
M. Gijsen, Omar Elkayal, P. Annaert, R. Van Daele, P. Meersseman, Y. Debaveye, J. Wauters, E. Dreesen, I. Spriet   +8 more
semanticscholar   +1 more source

Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients

Antimicrobial Agents and Chemotherapy, 2022
Several pathophysiological changes can alter meropenem pharmacokinetics in critically ill patients, thereby increasing the risk of subtherapeutic concentrations and affecting therapeutic outcomes.
Apinya Boonpeng, S. Jaruratanasirikul, Monchana Jullangkoon, Maseetoh Samaeng, Thitima Wattanavijitkul, R. Bhurayanontachai, S. Pattharachayakul   +6 more
semanticscholar   +1 more source

Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection.

Journal of Pharmacy and Science, 2022
PURPOSE This study aimed to develop a population pharmacokinetic (PPK) model for meropenem to optimize dosing regimens for critically ill patients with pulmonary infection. PATIENTS AND METHODS This prospective PPK study of meropenem was conducted on a
Jinhua Lan, Zheng Wu, Xipei Wang, Yifan Wang, Fen Yao, Bo Zhao, Yirong Wang, Jingchun Chen, Chunbo Chen   +8 more
semanticscholar   +1 more source

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients

Frontiers in Pharmacology, 2022
Routine clinical meropenem therapeutic drug monitoring data can be applied to model-informed precision dosing. The current study aimed to evaluate the adequacy and predictive capabilities of the published models with routine meropenem data and identify ...
Nan Yang, Jing Wang, Yue-Liang Xie, Junjie Ding, Cuifang Wu, Jingjing Liu, Qi Pei   +6 more
semanticscholar   +1 more source

Microbacterium spp. peritonitis in patients undergoing peritoneal dialysis: a single-center experience and literature review

Frontiers in Medicine, 2023
IntroductionPeritoneal dialysis-related peritonitis (PDRP) caused by Microbacterium spp. is very rare, with only 9 cases reported to date. In this study, we report the treatment experiences of 7 patients at our peritoneal dialysis center.MethodsWe ...
Xiao Yu, Xiao Yu, Zhao Li, Xinbo Yang, Xiaopei Wang, Di Nan, Wanhong Lu, Jing Lv, Ying Ma   +8 more
doaj   +1 more source

A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis.

Clinical Microbiology and Infection, 2022
OBJECTIVES In difficult to treat infections such as nosocomial ventriculitis, meropenem exposure in the infected compartment is often uncertain but crucial for antibacterial effects.
C. König, J. Grensemann, P. Czorlich, E. Schlemm, S. Kluge, S. Wicha   +5 more
semanticscholar   +1 more source

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018

Antibiotics, 2021
Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing K.
P. Gaibani, D. Lombardo, L. Bussini, Federica Bovo, B. Munari, M. Giannella, M. Bartoletti, P. Viale, T. Lazzarotto, S. Ambretti   +9 more
semanticscholar   +1 more source

The Case for Intermittent Carbapenem Dosing in Stable Haemodialysis Patients

Antibiotics, 2020
Purpose: Antimicrobial resistant infections are common in patients on haemodialysis, often needing long courses of carbapenems. This results in a longer hospital stay and risk of iatrogenic complications.
Vanda Ho, Felecia Tay, Jia En Wu, Lionel Lum, Paul Tambyah   +4 more
doaj   +1 more source

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Antibiotics, 2023
Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives.
Anna Duda-Madej, Szymon Viscardi, Ewa Topola   +2 more
doaj   +1 more source